has part has part has_part chemical inhibits protein chemical has protein target as antagonist chemical inhibits in vitro replication of virus has role has role dimethyl sulfoxide addition compound antineoplastic agent trametinib dimethyl sulfoxide N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide--(methylsulfinyl)methane (1/1) GSK1120212 PMID:22169769 Reaxys:12497280 C28H29FIN5O5S DrugBank:DB08911 PMID:23848983 PMID:24030134 Mekinist PMID:22507781 PMID:21245089 CS(C)=O.CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O An addition compound obtained by combining equimolar amounts of trametinib and dimethyl sulfoxide. Used for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment. GSK1120212B PMID:23432625 KEGG:D10176 693.09181 Patent:WO2005121142 OQUFJVRYDFIQBW-UHFFFAOYSA-N 0 PMID: 26868298 Trametinib DMSO PMID:24025354 PMID:23248257 https://www.drugbank.ca/drugs/DB08911 CAS:1187431-43-1 693.52800 JTP 74057 C26H23FIN5O4.C2H6OS chebi_ontology InChI=1S/C26H23FIN5O4.C2H6OS/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34;1-4(2)3/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34);1-2H3 PMID:22389471 Wikipedia:Trametinib CHEBI:75991 trametinib EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor Middle East respiratory syndrome-related coronavirus dual specificity mitogen-activated protein kinase kinase 2 (human) dual specificity mitogen-activated protein kinase kinase 1 (human)